



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 11 Nov 2019 (#38)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices & News

- **[NOT-AA-19-031](#): Notice of Special Interest on Neurobehavioral Mechanisms of Social Isolation and Alcohol Use Disorder (AUD)**. The purpose of this Notice of Special Interest (NOSI) is to support integrative research studies focusing on understanding the behavioral, cognitive, and neurobiological mechanisms underlying the interactions between social isolation and alcohol use disorder. Related Announcements:
 - [PA-19-055](#) - Research Project Grant (Parent R01 Clinical Trial Required)
 - [PA-19-056](#) - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
 - [PA-19-091](#) - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- **[NOT-AI-20-005](#): Notice of Special Interest: Advancing Research for Tickborne Diseases (TBDs)**. The purpose of this Notice is to announce that the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Mental Health (NIMH), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Center for Complementary and Integrative Health (NCCIH) encourage new applications to advance research activities relevant to the five strategic Related Announcements:
 - [PA-19-055](#) NIH Research Project Grant (Parent R01 Clinical Trial Required)
 - [PA-19-056](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
 - [PA-19-270](#) PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
 - [PA-19-272](#) PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
 - [PAR-19-134](#) Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed) priorities identified in the recently released [NIH Strategic Plan for Tickborne Disease](#)

1. Eradication of HIV-1 from Central Nervous system Reservoirs

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PA-17-084](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence and eradication strategies specifically focused on the central nervous system (CNS) in the context of viral suppression. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. HIV-1 infection of the Central Nervous System

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PA-17-100](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites research grant applications focused on defining and understanding the pathogenic mechanisms involved in Human Immunodeficiency Virus (HIV)-1 induced CNS dysfunction, but within the context of viral suppression and Antiretroviral therapy (ART). The FOA further supports research to identify therapeutic targets against which treatments may be developed to prevent the neurobehavioral and neurological co-morbidities in HIV-1 infected individuals. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-053](#)

Type: R01

Application Due Date: [Standard dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

4. Transgender People: Immunity, Prevention, and Treatment (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-054](#)

Type: R21

Application Due Date: **May 11, 2020; May 11, 2021.** Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

Budget: NIAID intends to fund an estimate of 2-5 awards, corresponding to a total of \$1.0 million, for fiscal year 2021. Future year amounts will depend on annual appropriations. The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The total project period may not exceed 2 years.

5. Step Up for Substance Use Disorders (SUD): A Drug Target Initiative for Scientists Engaged in Fundamental Research (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-DA-20-025](#)

Type: U18

Application Due Date: **February 13, 2020.** Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overall goal of The Step Up for SUD initiative is to advance fundamental discoveries into medicines to treat substance use disorders (SUD) for the benefit of society. The purpose of this funding opportunity is to enhance and accelerate research on drug targets for SUD aiming to expand the range of targets and mechanisms in development for SUD therapies. The initiative will provide both funding and the in-kind access to biomedical product development experts. It will be administered as a unique, short-term and nimble funding opportunity to support the confirmatory research in robust drug target validation/invalidation to allow for early decision to either proceed to a next step or stop the projects. At this point, only research projects on potential drug/biologic therapeutics, not diagnostics or devices, will be supported.

Budget: NIDA intends to fund an estimate of 50 awards, corresponding to a total of \$10 million for fiscal year 2020. Application budgets are limited to \$150,000 direct cost per year and must reflect the actual needs of the proposed project. Application budgets must only cover the work that will be performed by the PD/PI and his/her staff. The NIH will pay consultants directly for their work; therefore, these expenses must not be included in the budget for this application. The maximum project period is 1 year.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105